Heart HealthAHA Sets New Standards for Measuring Heart Risk in Cancer Drug Trials
Cancer treatments have dramatically improved survival, but many therapies carry cardiovascular risks — from heart failure to dangerous arrhythmias — that often go inconsistently reported across clinical trials. The American Heart Association has now released a scientific statement establishing standardized criteria for selecting, defining, and adjudicating cardiovascular endpoints in oncology trials. The framework links specific drug mechanisms to appropriate endpoint choices and aligns definitions of major adverse cardiac events with existing regulatory and clinical tools. It also offers guidance on decentralized trial designs, independent adjudication, and statistical methods for handling competing risks. The goal is to make cardiovascular safety data more reliable, comparable across studies, and ultimately more useful for protecting patients while advancing cancer drug development. This represents a major step toward integrating cardiology rigor into oncology research.
